DexCom is trading 4.01% down now at $82.30, with no clear company-specific explanation identified for the October 21 decline.
- The latest company coverage points to its October 29 earnings date and earlier clinical-trial results.
- The decline moved against the supplied healthcare-sector gain of 2.12% and broader market gains; available evidence does not establish a specific cause.